SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sustained rally to a 52-week high and push through a long-watched round-number level are driving attention, with holders celebrating the recovery while skeptics question whether it can hold without a stronger company-specific catalyst. Traders are also watching the upcoming earnings report and pipeline developments for confirmation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on reports that Trump ruled out an immediate U.S. strike on Iran, with many interpreting the news as a possible relief-driven futures bounce while others argue conflict and oil-supply risks are merely delayed. The debate is amplifying an already cautious, volatile outlook ahead of the Fed decision, major tech earnings and inflation data.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus stock-and-warrant offering has intensified concern about shareholder dilution and contributed to a steep selloff, alongside broader weakness in nuclear stocks. Traders are divided between viewing the pullback as a buying opportunity tied to domestic uranium-enrichment demand and worrying that valuation, expansion costs, and execution risks outweigh the long-term HALEU and DOE-contract potential.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

FDA clearance to expand Alpha Taus recurrent glioblastoma REGAIN trial and anticipated follow-up data are driving attention, alongside progress in its pancreatic cancer program. Traders are optimistic about the early GBM signal but acknowledge that it comes from a small cohort and await larger-data validation.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Discussion is focused on the $17.05 million investor settlement: eligible shareholders are being reminded to file claims before the deadline, with a final approval hearing scheduled immediately afterward. Some traders view clearing the legal overhang as a positive, while others emphasize the settlements limited per-share recovery and historical allegations about Twists production and financial disclosures.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened and rising rate expectations and yields weigh on precious metals and miners. Traders are divided between viewing the pullback and nearby support as a buying opportunity and expecting further losses if support gives way.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Volatile natural-gas futures are driving discussion, with traders weighing winter-weather demand and storage reports against mild-weather forecasts, strong production, and ample supply; pipeline and Freeport disruptions have also sparked sharp moves. Views are split on whether gas can sustain a rebound, while many warn that BOILs leveraged futures exposure and decay make it especially risky to hold.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and broader Middle East tensions could disrupt oil supplies and shipping. Bulls see tight supply and continued geopolitical risk supporting the move, while bears argue the rally may be overextended and could reverse if tensions ease or a deal emerges.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are focused on SQQQ as a leveraged hedge against the Nasdaq, citing tech weakness and concerns that heavy AI spending may not deliver adequate returns, alongside interest-rate and geopolitical risks. Some expect further downside in tech and favor SQQQ, while others caution that its daily leverage can erode value and that a Nasdaq rebound could reverse its gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer results for IMDELLTRA plus Imfinzi are drawing attention, with traders focused on the reported survival benefit and potential to expand the drugs role in earlier treatment. The community views the data as a meaningful pipeline catalyst, though some question how much it will change Amgens broader growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REX Shares to Close and Liquidate Two Funds

REX Shares (REX) today announced that the Board of Trustees (the Board) of REX ETF Trust (the Trust), based on the recommendation of REX Advisers, LLC (the Adviser), has approved the closure and liquidation of the REX IncomeMax Option Strategy ETF (Nasdaq: ULTI) and the Laddered T-Bill ETF (Cboe...

UiPath’s AI Automation Story Is Not Translating Into Faster Growth Yet, Say UBS, Morgan Stanley Analysts

Equity

Analysts at UBS reduced their price target for UiPath stock to $13 from $17 while maintaining a ‘Neutral’ rating.


Rocket Lab Plans Second Mission In 48 Hours – RKLB Stock Rises Premarket

The upcoming mission, dubbed ‘Follow My Speed,’ is slated to lift off on November 20 from Rocket Lab’s Launch Complex 1 in New Zealand. 

REX Shares Launches REX IncomeMax Option Strategy ETF (Ticker: ULTI)

REX Shares (REX), a leading innovator in alternative ETFs, today announced the launch of the REX IncomeMax Option Strategy ETF (Ticker: ULTI), an actively managed fund designed to capture weekly...

REX ETF Trust - REX IncomeMax Option Strategy ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Morgan Stanley analyst Sanjit Singh also trimmed his price target to $17 from $19.</li><li>Analysts say fourth-quarter results met expectations but see limited near-term upside due to modest growth.</li><li>UBS added constant-currency net new annual recurring revenue hasn’t meaningfully grown, signaling weak new business momentum.</li></ul>Shares of UiPath Inc. (PATH) remain under close watch after two major Wall Street firms revised their outlook for the automation software company following its fourth-quarter (Q4) results.&nbsp;Analysts say the company delivered results largely in line with expectations but see limited near-term upside amid modest growth trends.<h2 class="st-heading-2">UBS Cuts Target After Earnings Review</h2>Analysts at UBS reduced their price target for UiPath stock to $13 from $17 while maintaining a ‘Neutral’ rating, according to TheFly. The adjustment followed UiPath’s Q4 earnings update and forward guidance, which showed moderate growth expectations but lingering uncertainty around new subscription expansion.&nbsp;According to UBS, UiPath’s quarterly performance met Wall Street projections. The company also projected fiscal 2027 revenue growth of about 9% and annual recurring revenue growth of about 11%. While these estimates slightly exceed some investor expectations, the firm noted that constant-currency net new annual recurring revenue (NNARR) has yet to return to meaningful expansion, signaling subdued momentum in new business generation.<a href="https://stocktwits.com/symbol/PATH">UiPath stock</a> traded over 6% lower in Thursday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_12_070920_png_cb2ec31485.webp" alt="PATH’s Sentiment Meter and Message Volume as of 07:15 a.m. ET on Mar. 12, 2026 | Source: Stocktwits" width="928" height="107"><figcaption>PATH’s Sentiment Meter and Message Volume as of 07:15 a.m. ET on Mar. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Morgan Stanley Also Revises Price Target</h2>A similar stance came from Morgan Stanley analyst Sanjit Singh, who trimmed his price target to $17 from $19 while keeping an Equal Weight rating. Singh said that Q4 recurring revenue trends indicate resilience even as automation companies face a challenging demand environment.He added that UiPath’s fiscal 2027 annual recurring revenue guidance implies relatively flat net-new recurring revenue, suggesting stability rather than growth for the automation software sector during a period of broader economic uncertainty.PATH stock has gained over 4% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/s-and-p-500-could-drop-further-before-bottoming-says-morgan-stanley-chief-investment-officer-report/cZduTPYRI94">S&amp;P 500 Could Drop Another 5%-7% Before Bottoming, Says Morgan Stanley's Chief Investment Officer: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The UiPath logo is seen displayed on a smartphone screen next to a keyboard. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Analysts at UBS reduced their price target for UiPath stock to $13 from $17 while maintaining a ‘Neutral’ rating.

UiPath Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

ULTI News